Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.80 is 60% above its 2-year average of -9.43, near the high end of its 2-year range (-14.93–-2.99).
43.16% above its 12-month average of -6.69.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 8 comparable quarters.
EARNINGS PER SHARE (EPS)
-3.80
EARNINGS PER SHARE (EPS) AVG TTM
-6.69
EARNINGS PER SHARE (EPS) AVG 3Y
N/A
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+43.16%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$837.43M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.22
3Y Avg
-0.29
5Y Avg
-0.62
Market Cap
$852.55M
Earnings Per Share (EPS)
-1.68
TTM Avg
-1.54
3Y Avg
-1.41
5Y Avg
-1.41
Market Cap
$867.60M
Earnings Per Share (EPS)
-2.18
TTM Avg
-0.78
3Y Avg
-1.63
5Y Avg
-1.49
Market Cap
$819.44M
Earnings Per Share (EPS)
-0.20
TTM Avg
0.10
3Y Avg
-0.30
5Y Avg
-1.16
Market Cap
$786.48M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.28
3Y Avg
-0.16
5Y Avg
-0.10
Market Cap
$903.13M
Earnings Per Share (EPS)
-0.64
TTM Avg
-0.60
3Y Avg
-0.67
5Y Avg
-0.65
Market Cap
$780.95M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | -3.80 | -6.69 | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -0.23 | -0.22 | -0.29 | -0.62 |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -1.68 | -1.54 | -1.41 | -1.41 |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -2.18 | -0.78 | -1.63 | -1.49 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -0.20 | 0.10 | -0.30 | -1.16 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -0.62 | -0.28 | -0.16 | -0.10 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -0.64 | -0.60 | -0.67 | -0.65 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -1.68 | 0.05 | -1.18 | -0.72 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
Trailing EPS (TTM)
$-3.80
Forward EPS (Est.)
$-3.26
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2024-12-31 | -10.38 |
| 2023-12-31 | -2.99 |
| 2022-12-31 | -14.93 |
